See What HealthDay Can Do For You
Contact Us

Drug Interferes with Platelet Effects of Clopidogrel

Omeprazole reduces its ability to inhibit platelet reactivity

TUESDAY, Jan. 15 (HealthDay News) -- The proton pump inhibitor omeprazole reduces the ability of clopidogrel to inhibit platelet reactivity in patients undergoing coronary stent implantation, according to research published in the Jan. 22 issue of the Journal of the American College of Cardiology.

Martine Gilard, M.D., and colleagues from Brest University Hospital in Brest, France, randomly assigned 124 patients undergoing coronary stent implantation and receiving aspirin and clopidogrel to either 20 mg/day omeprazole or placebo for seven days.

The researchers found that the mean platelet reactivity index on day 1 was similar in both groups (83.2 and 83.9 percent in the placebo and omeprazole groups, respectively). On day 7, the mean platelet reactivity index was reduced to 39.8 percent in the placebo group and 51.4 percent in the omeprazole group, a statistically significant difference.

"Omeprazole significantly decreased clopidogrel inhibitory effect on platelet P2Y12 as assessed by vasodilator-stimulated phosphoprotein phosphorylation test," Gilard and colleagues write. "The clinical impact of these results remains uncertain but merits further investigation."

Full Text (subscription or payment may be required)

Physician's Briefing